Skip to Content
Merck
CN
  • Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly.

Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly.

Viruses (2023-06-28)
Jorge C G Blanco, Lori M Cullen, Arash Kamali, Fatouomata Y D Sylla, Marina S Boukhvalova, Trudy G Morrison
ABSTRACT

Respiratory syncytial virus (RSV) is a significant threat to elderly populations and repeated infections that occur throughout life are poorly protective. To assess the role of prior RSV infections as well as elderly immune senescence on vaccine efficacy, we compared immune responses after virus-like particle (VLP) immunization of elderly cotton rats and young cotton rats, both previously RSV infected, in order to mimic the human population. We show that immunization of RSV-experienced young or elderly animals resulted in the same levels of anti-pre-F IgG, anti-G IgG, neutralizing antibody titers, and protection from challenge indicating that the delivery of F and G proteins in a VLP is equally effective in activation of protective responses in both elderly and young populations. Our results suggest that F and G protein-containing VLPs induce anti-RSV memory established in prior RSV infections equally well in both young and elderly animals and thus can be an effective vaccine for the elderly.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-RSV Antibody, glycoprotein, all type A, B strains, clone 131-2G, clone 131-2G, from mouse